NASDAQ:AVGR - Avinger Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.3248 -0.01 (-2.99 %) (As of 12/14/2018 04:00 PM ET)Previous Close$0.3248Today's Range$0.32 - $0.345052-Week Range$0.27 - $10.20Volume933,785 shsAverage Volume2.28 million shsMarket Capitalization$7.79 millionP/E Ratio0.00Dividend YieldN/ABeta1.99 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat, and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company sells and markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California. Receive AVGR News and Ratings via Email Sign-up to receive the latest news and ratings for AVGR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVGR Previous Symbol CUSIPN/A Webwww.avinger.com Phone650-241-7900 Debt Debt-to-Equity RatioN/A Current Ratio1.12 Quick Ratio0.87 Price-To-Earnings Trailing P/E Ratio0.00 Forward P/E Ratio-0.05 P/E GrowthN/A Sales & Book Value Annual Sales$9.93 million Price / Sales0.77 Cash FlowN/A Price / Cash FlowN/A Book Value($42.82) per share Price / Book-0.01 Profitability EPS (Most Recent Fiscal Year)($70.07) Net Income$-48,730,000.00 Net Margins-416.08% Return on EquityN/A Return on Assets-158.54% Miscellaneous Employees65 Outstanding Shares23,460,000Market Cap$7.79 million OptionableNot Optionable Avinger (NASDAQ:AVGR) Frequently Asked Questions What is Avinger's stock symbol? Avinger trades on the NASDAQ under the ticker symbol "AVGR." When did Avinger's stock split? How did Avinger's stock split work? Avinger shares reverse split before market open on Wednesday, January 31st 2018. The 1-40 reverse split was announced on Tuesday, January 30th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 30th 2018. An investor that had 100 shares of Avinger stock prior to the reverse split would have 3 shares after the split. How were Avinger's earnings last quarter? Avinger Inc (NASDAQ:AVGR) released its earnings results on Tuesday, November, 13th. The medical device company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.05. The medical device company had revenue of $2.02 million for the quarter. View Avinger's Earnings History. When is Avinger's next earnings date? Avinger is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for Avinger. What is the consensus analysts' recommendation for Avinger? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avinger. Has Avinger been receiving favorable news coverage? News articles about AVGR stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avinger earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the near future. Are investors shorting Avinger? Avinger saw a decrease in short interest during the month of November. As of November 15th, there was short interest totalling 226,223 shares, a decrease of 87.8% from the October 31st total of 1,851,200 shares. Based on an average trading volume of 879,858 shares, the days-to-cover ratio is currently 0.3 days. Currently, 2.0% of the shares of the company are sold short. View Avinger's Current Options Chain. Who are some of Avinger's key competitors? Some companies that are related to Avinger include Lianluo Smart (LLIT), Interpace Diagnostics Group (IDXG), PAVmed (PAVM), DarioHealth (DRIO), Dynatronics (DYNT), Hancock Jaffe Laboratories (HJLI), Titan Medical (TMDI), Invivo Therapeutics (NVIV), CELLECT BIOTECH/S (APOP), Neovasc (NVCN), Biostage (BSTG), Alliqua Biomedical (ALQA), Presbia (LENS), Valeritas (VLRX) and Viatar CTC Solutions (VRTT). Who are Avinger's key executives? Avinger's management team includes the folowing people: Mr. Jeffrey M. Soinski, Pres, CEO & Director (Age 56)Mr. Matthew B. Ferguson, Consultant (Age 50)Dr. John Bush Simpson, Founder (Age 74)Mr. Mark B. Weinswig, Chief Financial Officer (Age 45)Mr. Keith Schaefer, Chief Operating Officer When did Avinger IPO? (AVGR) raised $60 million in an initial public offering on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company acted as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers. How do I buy shares of Avinger? Shares of AVGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Avinger's stock price today? One share of AVGR stock can currently be purchased for approximately $0.3248. How big of a company is Avinger? Avinger has a market capitalization of $7.79 million and generates $9.93 million in revenue each year. The medical device company earns $-48,730,000.00 in net income (profit) each year or ($70.07) on an earnings per share basis. Avinger employs 65 workers across the globe. What is Avinger's official website? The official website for Avinger is http://www.avinger.com. How can I contact Avinger? Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The medical device company can be reached via phone at 650-241-7900 or via email at [email protected] MarketBeat Community Rating for Avinger (NASDAQ AVGR)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 257 (Vote Outperform)Underperform Votes: 226 (Vote Underperform)Total Votes: 483MarketBeat's community ratings are surveys of what our community members think about Avinger and other stocks. Vote "Outperform" if you believe AVGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVGR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: What is cost of equity?